At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin for Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin. Completed, enrolled 58 participants across 22 sites in 5 countries.
Detailed Summary
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, France, United Kingdom, United States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionAug 2010
Study CompletionJun 2016
TodayJul 2026
First PostedMar 20, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2010
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.3 years ago
Interventions
brentuximab vedotindrug
1.8 mg/kg every 3 weeks by IV infusion